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facilitate shared decision making e.g. based on expected 
side-effects. The method was investigated for a large cohort 
of non-small cell lung cancer (NSCLC) patients treated with a 
dose-escalation protocol. 
Materials and Methods: All NSCLC patients treated in 2013 
with concurrent chemo-radiotherapy according to an 
institutional isotoxic dose-escalation protocol were included. 
The prescribed dose to the PTV was escalated up to 69 Gy 
keeping within the OAR dose constraints, e.g., a mean lung 
dose (MLD) of 20 Gy or a maximum spinal cord dose of 54 Gy. 
Patients were treated using volumetric modulated arc 
therapy. For 50 randomly selected patients (training cohort) 
the dose in the OAR voxels was calculated as function of the 
distance to the planning target volume (PTV). Next, for the 
lungs and spinal cord, the average dose-distance relation of 
the patients in the training cohort was calculated. For the 
remaining patients (validation cohort) these average-dose 
distance relations were used to predict dose-volume 
histograms (DVHs) based on the shape and orientation of the 
OARs and PTV. By scaling the DVHs of the OARs up to the 
dose constraints, the maximum achievable mean PTV dose 
could be predicted as well. The predicted and achieved DVHs 
were compared. 
Results: Of the 92 patients, 88 were retrieved and analysed 
and four excluded due to modified OAR constraints. The 
training and validation group consisted of 50 and 38 patients, 
respectively. The difference between the predicted and 
achieved MLD in the validation cohort was small and 
statistically insignificant (0.2 ± 1.8 Gy; p = 0.45) . The 
achieved mean PTV dose varied from 52 to 73 Gy and could 
be predicted correctly with an accuracy of 2 Gy for 87% of 
the patients. The spinal cord was dose limiting in only one 
patient and this was correctly predicted. Figure 1 presents 
the average dose-distance relations of all voxels in the lungs 
for the training group. The small variation in dose, especially 
in the region close to the PTV, emphasizes the usefulness of 
geometry-based plan comparison. 
 
Conclusions: We have shown that the MLD and the prescribed 
PTV dose could be accurately predicted for NSCLC patients 
treated with arc therapy prior to the treatment planning 
process. This method is suitable for other treatment sites as 
well can be used to guide the treatment planner to achieve 
optimal OAR sparing or tumour dose escalation. In addition, 
new personalized strategies of dose escalation and shared 
decision making are envisioned.  
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Purpose/Objective: There is a huge difference in 
radiosensitivity of lungs between patients, which may further 
individualise therapy. Moreover, if regional radiosensitivities 
could be quantified, radiation dose redistribution will 
become feasible. The present study aims to identify and 
quantify individual and regional radiosensitivity based on a 
single pre-treatment CT scan (CT0). 
Materials and Methods: 110 non-small cell lung cancer 
patients were studied: 40 treated with stereotactic ablative 
radiotherapy (SABR) for stage I (3x18 Gy, 4x12 Gy or 8x7.5 
Gy), 40 treated conventionally (CONV1) for stage III (24x2.75 
Gy sequential or 33x2 Gy concurrent with chemo), and 30 
treated conventionally (CONV2) from an external validation 
set (30x1.5 Gy followed by 12x2 Gy). 
A 3 month follow-up scan (CT3M) was non-rigidly registered to 
CT0. Lung volumes were segmented per dose bin of 5 Gy, and 
their median difference in Hounsfield Units was calculated 
(ΔHU=HU3M-HU0). Linear and sigmoidal fits (parameters 
ΔHUmax (saturation of ΔHU) and D50 (dose corresponding to 
50% of ΔHUmax)) were made for ΔHU versus local dose, both 
for physical dose (D) and equivalent dose (EQD2: 
alpha/beta=4 Gy, proliferation rate=0.44 Gy/day).  
Multivariate regression was performed for D50 and ΔHUmax 
using covariates PTV volume, tumour location, heart Dmax, 
median HU0 in the V40 region, overall treatment time (OTT), 
and timepoint of CT3M. 
This prognostic model defining sensitive individuals was 
tested to define sensitive regions within one lung. Therefore, 
two lung subvolumes with the highest possible difference in 
density were manually generated on CT0 (Figure 1). 
Results: Sigmoidal fits using EQD2 outperformed the other 
scenarios for SABR and CONV1: median sum of squares 
(CONV1 between brackets) of 170.0 (517.2), 187.7 (477.5), 
109.5 (326.6) and 100.7 (320.4) for linear (D), linear (EQD2), 
sigmoidal (D) and sigmoidal (EQD2) fits respectively. This was 
validated in CONV2: 685.1 and 527.5 for linear and sigmoidal 
EQD2 fits respectively. The distributions (in percent of 
patients) of D50 and ΔHUmax reflect a large sensitivity 
variation (Table 1). 
No prognostic factors were found for D50, while a higher 
baseline lung density (p=0.004) and left lung (p=0.05) were 
prognostic for higher ΔHUmax.  
The expected ΔHU were seen in selected subvolumes (Figure 
1). Redistribution IMRT plans avoiding the high density 
volumes were generated. Approximately 50% of patient lungs 
present a composition suitable for redistribution planning. 
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D50 (Gy) 
10-
20  
20-
30  
30-
40  
40-
50  
50-
60  
>60 
Unknown (no 
effect) 
CONV1 10.3 20.7 13.8 6.9 3.4 10.3 31.0 
CONV2 10.0 25.0 25.0 5.0 10.0 10.0 15.0 
SABR 15.2 27.3 12.1 12.1 9.1 9.1 15.2 
ΔHUmax 
(HU) 
10-
20 
20-
30 
30-
40 
40-
50 
50-
60 
>60 Unknown 
CONV1 13.8 13.8 13.8 13.8 0 13.8 31.0 
CONV2 10.0 35.0 15.0 5.0 10.0 10.0 15.0 
SABR 15.2 27.3 12.1 12.1 9.1 9.1 15.2 
Table 1 
 
 
 
Conclusions 
Baseline CT characteristics allow to identify patient-specific 
and regional differences in sensitivity for radiation-induced 
lung damage. This may be used for further treatment 
individualisation. 
This project has received funding from the European Union's 
Seventh Framework Programme under grant agreement no 
601826' (REQUITE). 
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Purpose/Objective: As urinary symptoms tend to recur 
throughout follow-up, conventional method of analysis using 
cumulative peak event and time-to-event may not be optimal 
to uncover the dosimetric-symptom correlates. We assessed 
the bladder dosimetry and urinary symptom correlates using 
longitudinally-defined endpoints and using recurrent event 
models which are contrasted to the conventional analysis 
methods. 
Materials and Methods: In this study, 754 dose-surface 
information and their corresponding specific urinary 
symptoms (dysuria (D), haematuria (H), incontinence (I) and 
frequency (F)) from a cohort of patients who received 
prostate radiotherapy in the RADAR TROG 03.04 trial were 
analysed. The dosimetric-symptom correlates were analysed 
using; 1) conventional methods (cumulative incidence(peak) 
and time-to-event(Cox) analysis), 2) longitudinally-defined 
endpoint (mean symptoms), 3) recurrent event models using 
the Andersen-Gill extension of the Cox regression model for 
counting process (AG) & generalised estimating equation 
(GEE) models. Dosimetric-symptom correlates were 
contrasted for the different analytic methods. 
Results: For dysuria and haematuria, stronger relationships 
were found to the dose indices using peak and Cox models 
compared to mean symptom, AG and GEE models. Despite 
the different strength of relationship, dose-surface of the 
bladder receiving higher than 65 Gy (S65) and S70 
consistently show strong relationship to dysuria. S60 to S65 
are the most significant for Hpeak , HGEE, HCox and Hmean. None 
of the dosimetric indices satisfy the proportional hazard 
assumption for HAG. For urinary incontinence and frequency, 
stronger relationships for dosimetric indices were found for 
AG, GEE and to lesser extent mean score model while both 
peak and Cox models do not result in significant or show 
trend towards significance. S35 to S40 were found to be the 
most significant for FGEE, Fmean and FAG while S20 to S25 for IAG 
and Imean. 
Conclusions: The use of peak or time-to-event model alone is 
not optimal in assessing dose-volume correlates for certain 
urinary symptoms endpoints. Dosimetric-symptom correlates 
analysis should be supplemented by longitudinally-defined 
endpoints and/or using recurrent event models to account for 
multiple events per patient.  
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Purpose/Objective: To assess clinical and dosimetric factors 
affecting acute urinary toxicities on a large cohort of patients 
treated with external beam radiotherapy (RT) for prostate 
cancer with radical intent. 
Materials and Methods: The final dataset of a prospective 
multicentre study was considered. It included 542 patients 
treated with conventionally (74-80 Gy at 1.8-2 Gy/fr) or 
